GSK PLC (GSK)
40.91
+0.05
(+0.12%)
USD |
NYSE |
Apr 25, 16:00
40.90
-0.02
(-0.04%)
After-Hours: 20:00
GSK Accounts Receivable (Quarterly): 7.522B for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 7.522B |
September 30, 2023 | 10.42B |
June 30, 2023 | 8.547B |
March 31, 2023 | 8.463B |
December 31, 2022 | 6.598B |
September 30, 2022 | 8.384B |
June 30, 2022 | 7.832B |
March 31, 2022 | 10.90B |
December 31, 2021 | 8.430B |
September 30, 2021 | 10.33B |
June 30, 2021 | 9.552B |
March 31, 2021 | 8.923B |
December 31, 2020 | 7.562B |
September 30, 2020 | 10.10B |
June 30, 2020 | 8.823B |
March 31, 2020 | 10.55B |
December 31, 2019 | 7.194B |
September 30, 2019 | 10.05B |
June 30, 2019 | 8.713B |
March 31, 2019 | 8.544B |
December 31, 2018 | 6.568B |
September 30, 2018 | 9.501B |
June 30, 2018 | 8.575B |
March 31, 2018 | 8.558B |
December 31, 2017 | 6.299B |
Date | Value |
---|---|
September 30, 2017 | 8.717B |
June 30, 2017 | 8.061B |
March 31, 2017 | 7.766B |
December 31, 2016 | 5.670B |
September 30, 2016 | 9.204B |
June 30, 2016 | 7.866B |
March 31, 2016 | 8.410B |
December 31, 2015 | 5.665B |
September 30, 2015 | 8.953B |
June 30, 2015 | 8.356B |
March 31, 2015 | 8.138B |
December 31, 2014 | 5.535B |
September 30, 2014 | 8.236B |
June 30, 2014 | 8.516B |
March 31, 2014 | 8.857B |
December 31, 2013 | 6.540B |
September 30, 2013 | 8.416B |
June 30, 2013 | 8.516B |
March 31, 2013 | 8.622B |
December 31, 2012 | 6.650B |
September 30, 2012 | 9.109B |
June 30, 2012 | 8.563B |
March 31, 2012 | 9.179B |
December 31, 2011 | 6.843B |
September 30, 2011 | 9.189B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
6.598B
Minimum
Dec 2022
10.90B
Maximum
Mar 2022
8.890B
Average
8.713B
Median
Jun 2019
Accounts Receivable (Quarterly) Benchmarks
AstraZeneca PLC | 8.407B |
Haleon PLC | 1.722B |
Novo Nordisk A/S | 9.617B |
Pfizer Inc | 11.18B |
Sanofi SA | 9.322B |